

EHA 2025 Congress

June 12–15, 2025
Milan, Italy



TOP ABSTRACTS

To help navigate the exciting content being presented at the 30th European Hematology Association (EHA) Congress, the GvHD Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in GvHD.

EHA 2025: Top abstracts in GvHD

June 12–15, 2025

Abstracts			
#	Title	Speaker	Day & time (CEST)
S255 View	JAK/ROCK inhibition with rovadicitinib suppresses murine and human acute graft-versus-host disease: The results of preclinical and phase 1b study	Yanmin Zhao	Thursday, June 12 17:00–17:15
S260 View	Pooled fecal allogenic microbiotherapy for refractory gastrointestinal acute graft-versus-host disease : Results from the early access program in Europe	Mohamad Mohty	Friday, June 13 17:00–17:15
S103 View	A phase 3 randomised trial of post-transplant cyclophosphamide for GvHD Prophylaxis in matched sibling donor peripheral blood stem cell transplantation: The ALLG BM12 CAST trial	David Curtis	Saturday, June 14 12:30–12:45

Posters		
#	Title	Author
PF392 View	Comparison of different doses of rabbit anti-thymocyte globulin (ATG-T) and anti-T-lymphocyte globulin (ATLG) in TBI-based myeloablative conditioning for haploidentical transplantation in acute lymphoblastic leukemia patients	Yue Lu
PF1034 View	Immune modulation in leukemia patients after hematopoietic stem cell transplantation with acute or chronic graft vs host disease (a/ cGvHD): 12-week extracorporeal photopheresis (ECP) reduces inflammatory and enhances inhibitory immune reactive cells	Anying Huang
PF1042 View	Unmet needs in cGvHD management: Real-world analysis of baseline and disease characteristics in European and Spanish patients previously treated with 2 to 5 lines of therapy	Carlos Solano
PF1043 View	Effect of anti-thymocyte globulin and post-transplant cyclophosphamide on GvHD outcomes in female-to-male matched unrelated donor allogeneic stem cell transplantation for acute leukemia	Nihar Desai
PF1072 View	Efficacy and safety of belumosudil monotherapy and combination with ruxolitinib in refractory chronic graft-versus-host-disease: A single centre, real-world experience	Vinay Anand Guntiboina
PF1090 View	Trial in progress: A randomized, open-label, phase 3 study of axatilimab versus best available therapy in patients with chronic graft-versus-host disease after ≥ 2 prior lines of systemic therapy	Mi Kwon
PS2027 View	A randomized trial of three GvHD prophylaxis regimens in haploidentical peripheral blood stem cell transplant: Antithymocyte globulin, posttransplant cyclophosphamide, and low-dose combination therapy	Yannan Jia
PS2031 View	MAAT033 to ensure optimal gut microbiota to improve survival in patients receiving allogeneic HCT: PHOEBUS trial	Natalia Gemperle Ortiz



#EHA2025

Follow us on X to keep up to date
with the latest from the congress

@GvHD_Hub



Brought to you by

